Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed a share repurchase conducted on 11 September 2026 under its existing buy-back mandate approved on 16 June 2026.

Key transaction details • Volume and proportion: 1.34 million H-shares, representing 0.25% of the company’s issued share capital (excluding treasury shares) prior to the transaction. • Price range: HKD 16.14 to HKD 16.50 per share; volume-weighted average price of HKD 16.32. • Consideration: HKD 21.86 million.

Impact on share capital structure (H-shares) • Issued shares (excluding treasury shares) decreased from 538.91 million to 537.57 million. • Treasury shares rose from 13.03 million to 14.37 million. • Total issued shares remained unchanged at 551.94 million.

Repurchase mandate utilisation • Authorised limit: 54.10 million shares. • Cumulative repurchases under the mandate: 3.40 million shares, equal to 0.63% of the issued share count on the mandate date. • Remaining authority: 50.69 million shares.

Post-transaction restrictions In accordance with Hong Kong Listing Rules, Fosun Pharma is subject to a moratorium on new share issues or treasury share disposals until 11 October 2026.

The company confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the explanatory statement issued on 11 May 2026.